.png)
Powered by WallStreetSectors.com
According to WallStreetSectors.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at WallStreetSectors.com, are adding the stocks below to their healthtech stock watchlist. That staff here at preciousmetalsplaybook.com, will continue to monitor these healthtech companies to see if the momentum continues. This is the Site Category description..
Recent INSM Stock Price: $20.85
Summary: Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.
Graig Suvannavejh analyst at Mizuho Securities reiterates coverage on Insmed (INSM) stock in the energy sector with a Buy rating and has set INSM's stock price target at $ 28.
TipRanks.com reports that Insmed currently has 5 analysts offering 12-month price targets on INSM and the consensus is a Strong Buy rating with an average stock price target of $34.80. The most recent INSM stock price we have is $20.85 and we are not making any INSM forecasts at this time.
In addition, TradingView issued a Buy rating for INSM over the next month, Barchart.com has a hold rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on INSM. preciousmetalsplaybook.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on INSM, please click here >>
Apellis Pharmaceuticals, APLS
Recent APLS Stock Price: $68.81
Summary: Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.
Steven Seedhouse analyst at Raymond James reiterates coverage on Apellis Pharmaceuticals (APLS) stock in the energy sector with a Buy rating and has set APLS's stock price target at $ 139.
TipRanks.com reports that Apellis Pharmaceuticals currently has 12 analysts offering 12-month price targets on APLS and the consensus is a Strong Buy rating with an average stock price target of $83.92. The most recent APLS stock price we have is $68.81 and we are not making any APLS forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for APLS over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on APLS. preciousmetalsplaybook.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on APLS, please click here >>
4D Molecular Therapeutics, FDMT
Recent FDMT Stock Price: $20.70
Summary: 4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.
Matthew Caufield analyst at H.C. Wainwright reiterates coverage on 4D Molecular Therapeutics (FDMT) stock in the energy sector with a Buy rating and has set FDMT's stock price target at $ 36.
TipRanks.com reports that 4D Molecular Therapeutics currently has 4 analysts offering 12-month price targets on FDMT and the consensus is a Strong Buy rating with an average stock price target of $32.00. The most recent FDMT stock price we have is $20.70 and we are not making any FDMT forecasts at this time.
In addition, TradingView issued a Buy rating for FDMT over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on FDMT. preciousmetalsplaybook.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on FDMT, please click here >>
Seagen, SGEN
Recent SGEN Stock Price: $161.71
Summary: Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries. Seagen has an agreement with Takeda Pharmaceutical Company Ltd. for the further development and commercialization of Adcetris. Seagen retains all rights to sell Adcetris in the U.S. and Canada, while Takeda has commercial rights to the drug in the rest of the world. The FDA granted approvals to Seagen's several drugs named Padcev, for treating advanced/metastatic urothelial cancer; Tukysa and Tivdak for treating adult patients with locally advanced/metastatic HER2-positive breast cancer and for the treatment of recurrent/metastatic cervical cancer in adult patients respectively. The company also has license agreements with partners like Merck, Roche, GlaxoSmithKline, Astellas, AbbVie, Bristol-Myers and Genmab.
Ami Fadia analyst at Needham reiterates coverage on Seagen (SGEN) stock in the energy sector with a Buy rating and has set SGEN's stock price target at $ 178.
TipRanks.com reports that Seagen currently has 18 analysts offering 12-month price targets on SGEN and the consensus is a Strong Buy rating with an average stock price target of $165.47. The most recent SGEN stock price we have is $161.71 and we are not making any SGEN forecasts at this time.
In addition, TradingView issued a Buy rating for SGEN over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SGEN. preciousmetalsplaybook.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SGEN, please click here >>
The editors at preciousmetalsplaybook.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
This is the site description.
==============================================================================
